American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 773-799 , May 2010

KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)

  • Katrin Uhlig, MD, MS

      Affiliations

    • Tufts Medical Center, Tufts University School of Medicine, Boston MA
    • Corresponding Author InformationAddress correspondence to Katrin Uhlig, MD, MS, Tufts Medical Center, Box 391, 800 Washington St, Boston MA 02445
    • ,
  • Jeffrey S. Berns, MD

      Affiliations

    • University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Bryan Kestenbaum, MD, MS

      Affiliations

    • University of Washington Kidney Research Institute, Seattle, WA
    • ,
  • Raj Kumar, MBBS

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, MN
    • ,
  • Mary B. Leonard, MD

      Affiliations

    • The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Kevin J. Martin, MB, BCh

      Affiliations

    • Division of Nephrology, Saint Louis University, St. Louis, MO
    • ,
  • Stuart M. Sprague, DO

      Affiliations

    • North Shore University Health System University of Chicago Pritzker School of Medicine, Chicago, IL
    • ,
  • Stanley Goldfarb, MD

      Affiliations

    • University of Pennsylvania School of Medicine, Philadelphia, PA

References 

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130
  2. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66(4):1310–1314
  3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–1953
  4. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490–1497
  5. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology (A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)). Kidney Int. 2006;70(12):2058–2065
  6. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049–1051
  7. Fervers B, Remy-Stockinger M, Graham ID, et al. Guideline adaptation: an appealing alternative to de novo guideline development. Ann Intern Med. 2008;148(7):563–564author reply 564-565
  8. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202
  9. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children With CKD: 2008 update. Am J Kidney Dis. 2009;53(suppl 2):S1–S124
  10. Centers for Medicare & Medicaid Services. End-stage renal disease prospective payment system (Proposed rule and notice). Fed Regist. 2009;74(187):49923–50102
  11. Weiner DE, Watnick SG. The 2009 proposed rule for prospective ESRD payment: historical perspectives and public policies—bundle up!. Am J Kidney Dis. 2010;55(2):217–222
  12. Nissenson AR, Mayne TJ, Krishnan M. The 2009 proposed rule for prospective ESRD payment: perspectives from a large dialysis organization. Am J Kidney Dis. 2010;55(2):223–226
  13. Moran J. The 2009 proposed rule for prospective ESRD payment: perspectives from a medium-sized dialysis organization. Am J Kidney Dis. 2010;55(2):227–228
  14. Sadler JH. The 2009 proposed rule for prospective ESRD payment: perspectives from a not-for-profit small dialysis organization. Am J Kidney Dis. 2010;55(2):229–230
  15. Bhat JG, Bhat P. The 2009 proposed rule for prospective ESRD payment: perspectives from a for-profit small dialysis organization. Am J Kidney Dis. 2010;55(2):231–233
  16. Kristensen C, Wish J. The 2009 proposed rule for prospective ESRD payment: perspectives from the forum of ESRD Networks. Am J Kidney Dis. 2010;55(2):234–236
  17. Norman ME, Mazur AT, Borden S, et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr. 1980;97(2):226–232
  18. Gauci C, Moranne O, Fouqueray B, et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol. 2008;19(8):1592–1598
  19. Urena P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7(3):506–512
  20. Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13(9):2294–2302
  21. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74(5):655–663
  22. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19(11):2193–2203
  23. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780
  24. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–38
  25. Urena P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 11995;0(6):932-939.
  26. Binkley N, Krueger D, Lensmeyer G. 25-Hydroxyvitamin D measurement, 2009: a review for clinicians. J Clin Densitometry. 2009;12(4):417–427
  27. Zidehsarai MP, Moe SM. Review article: chronic kidney disease-mineral bone disorder: have we got the assays right?. Nephrology. 2009;14(4):374–382
  28. Jones G, Horst R, Carter G, et al. Contemporary diagnosis and treatment of vitamin D-related disorders. J Bone Miner Res. 2007;22(suppl 2):V11–V15
  29. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S–1086S
  30. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial. 2005;18(4):266–275
  31. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol. 2008;624:31–42
  32. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004–1013
  33. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–1591
  34. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1555–1560
  35. Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009;54(4):647–652
  36. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68(6):2823–2828
  37. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–456
  38. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr. 2006;136(4):1117–1122
  39. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204–210
  40. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68(4):854–858
  41. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617
  42. Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (KDOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005;46(5):925–932
  43. Ketteler M, Brandenburg V, Jahnen-Dechent W. Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol Dial Transplant. 2005;20:673–677
  44. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int. 2007;72(7):792–796
  45. Tentori F, Blayney M, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and parathyroid hormone: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–530
  46. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77(2):93–100
  47. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay—importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab. 2005;51(1-2):21–29
  48. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70(2):345–350
  49. Joly D, Drueke TB, Alberti C, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51(6):987–995
  50. Cavalier E, Rozet E, Gadisseur R, et al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs [published online ahead of print September 9, 2009]. Osteoporos Int. doi 10.1007/s00198-009-1052-5.
  51. Elder GJ, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res. 2006;21(11):1778–1784
  52. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis. 2007;49(5):6746–6781
  53. Jamal SA, Gilbert J, Gordon C, et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006;21(4):543–548
  54. Carmen SM, Auxiliadora BM, Selgas R, et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis. 2000;36(5):953–961
  55. Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41(5):997–1007
  56. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol. 2005;63(4):284–289
  57. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483
  58. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients (A link between end-stage renal disease and cardiovascular disease?). J Am Coll Cardiol. 2002;39(4):695–701
  59. Uhlig K. There is no practical utility in routinely screening dialysis patients for vascular calcification. Semin Dial., in press.
  60. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218
  61. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179–1187
  62. Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study. Hemodial Int. 2007;11(3):340–348
  63. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–528
  64. Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis. 2005;46(3):455–463
  65. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–1096
  66. Hou SH, Zhao J, Ellman CF, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis. 1991;18(2):217–224
  67. Argiles A, Kerr PG, Canaud B, et al. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int. 1993;43(3):630–640
  68. Sigrist M, McIntyre CW. Calcium exposure and removal in chronic hemodialysis patients. J Ren Nutr. 2006;16(1):41–46
  69. Gotch F, Levin NW, Kotanko P. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010;29(2):163–176
  70. Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol. 2003;14(9):2322–2328
  71. Toussaint ND, Polkinghorne KR, Kerr PG, et al. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Hemodial Int. 2007;11(2):217–224
  72. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54(4):619–637
  73. Kalantar-Zadeh K, Gutekunst L, Mehrotra R. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519–530
  74. Sherman RA, Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis. 2009;54(1):18–23
  75. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8):1370–1373
  76. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298(11):1291–1299
  77. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(4):CD008175
  78. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441
  79. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2105–2115
  80. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–508
  81. Ishani A, Blackwell T, Jamal SA, et al. The effect of raloxifene treament in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19:1430–1438
  82. Cunningham J. Bisphosphonates in the renal patient. Nephrol Dial Transplant. 2007;22(6):1505–1507
  83. Vimalachandra D, Hodson EM, Willis NS, et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2006;3:CD003264
  84. Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients—a review. Am J Nephrol. 2008;28(2):246–253
  85. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–550
  86. El-Husseini AA, El-Agroudy AE, El-Sayed MF, et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant. 2004;8(4):357–361
  87. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX (Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group). JAMA. 1999;282(8):771–778

 Originally published online as doi:10.1053/j.ajkd.2010.02.340 on April 5, 2010.

 Reprint requests to Kerry Willis, PhD, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: kerryw@kidney.org

PII: S0272-6386(10)00489-0

doi: 10.1053/j.ajkd.2010.02.340

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 773-799 , May 2010

Article Tools